Site search

Clear filter
2898 results for '' found
Toxicity Reduction with Urethra Sparing radiation Therapy for prostate cancer (ACTRN12625000487415)
Toxicity Reduction with Urethra Sparing radiation Therapy for prostate cancer (ACTRN12625000487415)
/
Evaluation of Outcomes Following Tricuspid Valve Cylinder Reconstruction in Isolated Severe Tricuspid Regurgitation (ACTRN12620000564954p)
/
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kid
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kid
/
A Feasibility Trial of Tranexamic Acid for Necrotising Soft-Tissue Infections (ACTRN12621001423808)
A Feasibility Trial of Tranexamic Acid for Necrotising Soft-Tissue Infections (ACTRN12621001423808)
/
Tranexamic acid to Reduce Infection after Gastrointestinal Surgery: the TRIGS Trial (NCT04192435)
Tranexamic acid to Reduce Infection after Gastrointestinal Surgery: the TRIGS Trial (NCT04192435)
/
TRICS IV: Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery. An international, multi-centre, randomized controlled trial to assess (NCT04754022)
TRICS IV: Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery. An international, multi-centre, randomized controlled trial to assess (NCT04754022)
/
A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibros
A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibros
/
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBOCONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NO
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBOCONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NO
/
Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease (NCT05508789)
Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease (NCT05508789)
/
Assessment of Safety, Tolerability, and Efficacy of LY3002813 in Early Symptomatic Alzheimer’s Disease (NCT04437511)
Assessment of Safety, Tolerability, and Efficacy of LY3002813 in Early Symptomatic Alzheimer’s Disease (NCT04437511)
/
13 14 15 16 17